A	O
Novel	O
BRCA1	B:C1368335
-	I:C1368335
Associated	I:C1368335
Protein	I:C1368335
-	I:C1368335
1	I:C1368335
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	O
Cells	I:C0025500
to	O
Drugs	O
Impairing	O
BRCA1	O
-	O
Mediated	O
DNA	O
Repair	I:C0012899
.	O

A	O
Novel	O
BRCA1	O
-	I:C1368335
Associated	I:C1368335
Protein	I:C1368335
-	I:C1368335
1	I:C1368335
Isoform	B:C0597298
Affects	O
Response	O
of	O
Mesothelioma	O
Cells	I:C0025500
to	O
Drugs	O
Impairing	O
BRCA1	O
-	O
Mediated	O
DNA	O
Repair	I:C0012899
.	O

A	O
Novel	O
BRCA1	O
-	I:C1368335
Associated	I:C1368335
Protein	I:C1368335
-	I:C1368335
1	I:C1368335
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	B:C0025500
Cells	I:C0025500
to	O
Drugs	O
Impairing	O
BRCA1	O
-	O
Mediated	O
DNA	O
Repair	I:C0012899
.	O

A	O
Novel	O
BRCA1	O
-	I:C1368335
Associated	I:C1368335
Protein	I:C1368335
-	I:C1368335
1	I:C1368335
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	O
Cells	I:C0025500
to	O
Drugs	B:C0013227
Impairing	O
BRCA1	O
-	O
Mediated	O
DNA	O
Repair	I:C0012899
.	O

A	O
Novel	O
BRCA1	O
-	I:C1368335
Associated	I:C1368335
Protein	I:C1368335
-	I:C1368335
1	I:C1368335
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	O
Cells	I:C0025500
to	O
Drugs	O
Impairing	O
BRCA1	B:C1528558
-	O
Mediated	O
DNA	O
Repair	I:C0012899
.	O

A	O
Novel	O
BRCA1	O
-	I:C1368335
Associated	I:C1368335
Protein	I:C1368335
-	I:C1368335
1	I:C1368335
Isoform	O
Affects	O
Response	O
of	O
Mesothelioma	O
Cells	I:C0025500
to	O
Drugs	O
Impairing	O
BRCA1	O
-	O
Mediated	O
DNA	B:C0012899
Repair	I:C0012899
.	O

BRCA1	B:C1368335
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	O
histone	O
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	B:C1368335
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	O
histone	O
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	B:C0597611
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	O
histone	O
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	B:C0007613
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	O
histone	O
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	B:C1158770
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	O
histone	O
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	B:C1156197
modification	I:C1156197
by	O
deubiquitinating	O
histone	O
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	B:C1157996
histone	O
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	O
histone	B:C0147579
2A	I:C0147579
,	O
and	O
DNA	O
repair	I:C0012899
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
)	O
is	O
a	O
tumor	O
suppressor	I:C0597611
involved	O
in	O
multiple	O
cellular	O
processes	I:C0007613
such	O
as	O
transcriptional	O
regulation	I:C1158770
,	O
chromatin	O
modification	I:C1156197
by	O
deubiquitinating	O
histone	O
2A	I:C0147579
,	O
and	O
DNA	B:C0012899
repair	I:C0012899
.	O

BRCA1	B:C1368335
associated	I:C1368335
protein1	I:C1368335
mutations	O
are	O
frequent	O
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
(	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
)	O
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
mutations	B:C0026882
are	O
frequent	O
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
(	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
)	O
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
mutations	O
are	O
frequent	O
in	O
malignant	B:C0812413
pleural	I:C0812413
mesothelioma	I:C0812413
(	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
)	O
.	O

BRCA1	O
associated	I:C1368335
protein1	I:C1368335
mutations	O
are	O
frequent	O
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
(	O
malignant	B:C0812413
pleural	I:C0812413
mesothelioma	I:C0812413
)	O
.	O

Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	B:C0597298
of	O
BAP1	I:C1368335
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	O
on	O
drug	O
sensitivity	O
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
.	O

Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	O
of	B:C1368335
BAP1	I:C1368335
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	O
on	O
drug	O
sensitivity	O
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
.	O

Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	O
of	O
BAP1	I:C1368335
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	B:C0017262
on	O
drug	O
sensitivity	O
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
.	O

Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	O
of	O
BAP1	I:C1368335
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	O
on	O
drug	O
sensitivity	O
in	O
malignant	B:C0812413
pleural	I:C0812413
mesothelioma	I:C0812413
.	O

Expression	B:C0017262
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	O
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	B:C1368335
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	O
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	B:C0442726
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	O
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	B:C2733022
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	O
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	B:C0812413
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	O
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	B:C0086610
cell	O
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	B:C0007600
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	O
lines	I:C0007600
and	O
tumor	B:C0475358
and	O
nontumor	O
samples	I:C1292533
.	O

Expression	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
detected	O
by	O
quantitative	O
polymerase	I:C2733022
chain	I:C2733022
reaction	I:C2733022
in	O
malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
and	O
normal	O
mesothelium	O
cell	O
lines	I:C0007600
and	O
tumor	O
and	O
nontumor	B:C1292533
samples	I:C1292533
.	O

Histone	B:C0019646
H2A	I:C0019646
ubiquitination	O
levels	O
were	O
analyzed	O
by	O
Western	O
blot	I:C0949466
after	O
acidic	O
extraction	I:C0684295
of	O
core	O
histones	I:C2987130
.	O

Histone	O
H2A	I:C0019646
ubiquitination	B:C1156207
levels	O
were	O
analyzed	O
by	O
Western	O
blot	I:C0949466
after	O
acidic	O
extraction	I:C0684295
of	O
core	O
histones	I:C2987130
.	O

Histone	O
H2A	I:C0019646
ubiquitination	O
levels	O
were	O
analyzed	B:C0936012
by	O
Western	O
blot	I:C0949466
after	O
acidic	O
extraction	I:C0684295
of	O
core	O
histones	I:C2987130
.	O

Histone	O
H2A	I:C0019646
ubiquitination	O
levels	O
were	O
analyzed	O
by	O
Western	B:C0949466
blot	I:C0949466
after	O
acidic	O
extraction	I:C0684295
of	O
core	O
histones	I:C2987130
.	O

Histone	O
H2A	I:C0019646
ubiquitination	O
levels	O
were	O
analyzed	O
by	O
Western	O
blot	I:C0949466
after	O
acidic	B:C0684295
extraction	I:C0684295
of	O
core	O
histones	I:C2987130
.	O

Histone	O
H2A	I:C0019646
ubiquitination	O
levels	O
were	O
analyzed	O
by	O
Western	O
blot	I:C0949466
after	O
acidic	O
extraction	I:C0684295
of	O
core	B:C2987130
histones	I:C2987130
.	O

Subcellular	B:C3893246
localization	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
examined	O
by	O
immunofluorescence	O
.	O

Subcellular	O
localization	O
of	O
BRCA1	B:C1368335
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
examined	O
by	O
immunofluorescence	O
.	O

Subcellular	O
localization	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	B:C0597298
was	O
examined	O
by	O
immunofluorescence	O
.	O

Subcellular	O
localization	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
examined	B:C0332128
by	O
immunofluorescence	O
.	O

Subcellular	O
localization	O
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
isoforms	O
was	O
examined	O
by	O
immunofluorescence	B:C0079603
.	O

malignant	B:C0812413
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	B:C0007620
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	B:C0032405
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	B:C0032405
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	B:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	B:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	B:C1307407
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	B:C1307407
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	B:C0014432
was	O
analyzed	O
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	B:C0936012
by	O
in	O
vitro	I:C1515653
assays	I:C1515653
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
survival	I:C0007620
in	O
response	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
(	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
)	O
and	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
(	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
)	O
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
(	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
)	O
inhibitors	O
was	O
analyzed	O
by	O
in	B:C1515653
vitro	I:C1515653
assays	I:C1515653
.	O

We	O
have	O
identified	O
a	O
novel	O
alternative	B:C1720834
splice	I:C1720834
isoform	I:C1720834
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BAP1	O
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	O
domain	I:C0600499
.	O

We	O
have	O
identified	O
a	O
novel	O
alternative	O
splice	I:C1720834
isoform	I:C1720834
of	O
BRCA1	B:C1368335
associated	I:C1368335
protein1	I:C1368335
(	O
BAP1	O
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	O
domain	I:C0600499
.	O

We	O
have	O
identified	O
a	O
novel	O
alternative	O
splice	I:C1720834
isoform	I:C1720834
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BAP1	B:C1332380
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	O
domain	I:C0600499
.	O

We	O
have	O
identified	O
a	O
novel	O
alternative	O
splice	I:C1720834
isoform	I:C1720834
of	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
(	O
BAP1	O
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	B:C0600499
domain	I:C0600499
.	O

Cells	B:C0007634
transfected	O
with	O
BAP1	O
showed	O
reduced	O
deubiquitinating	O
activity	I:C1157996
compared	O
with	O
full	O
-	O
length	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
.	O

Cells	O
transfected	B:C0040669
with	O
BAP1	O
showed	O
reduced	O
deubiquitinating	O
activity	I:C1157996
compared	O
with	O
full	O
-	O
length	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
.	O

Cells	O
transfected	O
with	O
BAP1	B:C1332380
showed	O
reduced	O
deubiquitinating	O
activity	I:C1157996
compared	O
with	O
full	O
-	O
length	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
.	O

Cells	O
transfected	O
with	O
BAP1	O
showed	O
reduced	O
deubiquitinating	B:C1157996
activity	I:C1157996
compared	O
with	O
full	O
-	O
length	O
BRCA1	O
associated	I:C1368335
protein1	I:C1368335
.	O

Cells	O
transfected	O
with	O
BAP1	O
showed	O
reduced	O
deubiquitinating	O
activity	I:C1157996
compared	O
with	O
full	O
-	O
length	O
BRCA1	B:C1368335
associated	I:C1368335
protein1	I:C1368335
.	O

The	O
expression	B:C0017262
of	O
BAP1	O
transcript	O
is	O
more	O
abundant	O
in	O
nontumor	O
than	O
in	O
tumor	O
samples	O
.	O

The	O
expression	O
of	O
BAP1	B:C1332380
transcript	O
is	O
more	O
abundant	O
in	O
nontumor	O
than	O
in	O
tumor	O
samples	O
.	O

The	O
expression	O
of	O
BAP1	O
transcript	B:C1519595
is	O
more	O
abundant	O
in	O
nontumor	O
than	O
in	O
tumor	O
samples	O
.	O

The	O
expression	O
of	O
BAP1	O
transcript	O
is	O
more	O
abundant	O
in	O
nontumor	B:C1292533
than	O
in	O
tumor	O
samples	O
.	O

malignant	B:C0812413
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	B:C0085983
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	B:C0017262
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	B:C1332380
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	B:C2316164
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	B:C1567710
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	B:C0014432
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	B:C0596402
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	B:C2316164
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	B:C3887704
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	B:C2984520
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	B:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	B:C1307407
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	B:C0014432
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	B:C0013081
of	O
BRCA1	O
.	O

malignant	O
pleural	I:C0812413
mesothelioma	I:C0812413
cell	O
lines	I:C0085983
expressing	O
more	O
than	O
20	O
%	O
of	O
BAP1	O
are	O
more	O
sensitive	O
to	O
olaparib	O
(	O
a	O
PARP1	O
inhibitor	O
)	O
cytotoxicity	O
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	O
treatment	O
is	O
combined	O
with	O
GDC0980	O
(	O
a	O
dual	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitor	O
)	O
,	O
which	O
induces	O
downregulation	O
of	O
BRCA1	B:C1528558
.	O

These	O
observations	B:C0302523
suggest	O
that	O
BAP1	O
does	O
regulate	O
DNA	I:C3270705
damage	I:C3270705
response	I:C3270705
and	O
influences	O
drug	O
sensitivity	O
.	O

These	O
observations	O
suggest	O
that	O
BAP1	B:C1332380
does	O
regulate	O
DNA	I:C3270705
damage	I:C3270705
response	I:C3270705
and	O
influences	O
drug	O
sensitivity	O
.	O

These	O
observations	O
suggest	O
that	O
BAP1	O
does	O
regulate	B:C3270705
DNA	I:C3270705
damage	I:C3270705
response	I:C3270705
and	O
influences	O
drug	O
sensitivity	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	B:C0017262
of	O
BAP1	O
may	O
be	O
responsive	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
/	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitors	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1	B:C1332380
may	O
be	O
responsive	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
/	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitors	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1	O
may	O
be	O
responsive	B:C0521982
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
/	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitors	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1	O
may	O
be	O
responsive	O
to	O
poly	B:C0032405
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
/	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitors	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1	O
may	O
be	O
responsive	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
/	O
phosphoinositide	B:C0044602
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitors	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1	O
may	O
be	O
responsive	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
/	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	B:C1307407
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitors	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	O
of	O
BAP1	O
may	O
be	O
responsive	O
to	O
poly	O
(	I:C0032405
adenosine	I:C0032405
diphosphate	I:C0032405
-	I:C0032405
ribose	I:C0032405
)	I:C0032405
polymerase	I:C0032405
/	O
phosphoinositide	O
3	I:C0044602
-	I:C0044602
kinase	I:C0044602
-	O
mammalian	O
target	I:C1307407
of	I:C1307407
rapamycin	I:C1307407
inhibitors	B:C0014432
.	O

